FBRX Stock Price, Forte Biosciences, Inc. Quote, Chart

Market Summary

USD0.72-0.02

Market Closed

-2.70%

FBRX Stock Price

View Fullscreen

FBRX RSI Chart

FBRX Valuation

Market Cap

26.2M

Price/Earnings (Trailing)

-0.83

Price/Sales (Trailing)

647.02

EV/EBITDA

-0.19

Price/Free Cashflow

-0.91

FBRX Price/Sales (Trailing)

FBRX Profitability

EBT Margin

-132238.89%

Return on Equity

-89.13%

Return on Assets

-80.75%

Free Cashflow Yield

-109.88%

FBRX Fundamentals

FBRX Revenue

Revenue (TTM)

36.0K

FBRX Earnings

Earnings (TTM)

-31.5M

Earnings Growth (Yr)

-20.4%

Earnings Growth (Qtr)

41.01%

Breaking Down FBRX Revenue

Last 7 days

-1.4%

Last 30 days

4.4%

Last 90 days

-4%

Trailing 12 Months

-31.4%

How does FBRX drawdown profile look like?

FBRX Financial Health

Current Ratio

10.45

Debt/Equity

0.63

Debt/Cashflow

-1.3

FBRX Investor Care

Shares Dilution (1Y)

73.02%

Diluted EPS (TTM)

-1.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	0	0	0	0
2019	13.5M	9.0M	4.5M	36.0K
2018	438.0K	666.0K	18.7M	18.0M
2017	76.8K	104.5K	132.3K	160.0K
2016	106.8K	87.5K	68.3K	49.0K
2015	0	0	0	126.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Forte Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	wagner paul a.	sold (taxes)	-1,735	0.7075	-2,453	see remarks
Apr 01, 2024	wagner paul a.	acquired	-	-	31,250	see remarks
Apr 01, 2024	riley antony a	sold (taxes)	-2,366	0.7075	-3,345	chief financial officer
Apr 01, 2024	riley antony a	acquired	-	-	9,375	chief financial officer
Jan 01, 2024	chen hubert c	sold (taxes)	-2,525	0.8217	-3,073	see remarks
Jan 01, 2024	chen hubert c	acquired	-	-	7,500	see remarks
Jan 01, 2024	wagner paul a.	sold (taxes)	-3,376	0.8217	-4,109	see remarks
Jan 01, 2024	wagner paul a.	acquired	-	-	31,250	see remarks
Jan 01, 2024	riley antony a	sold (taxes)	-3,156	0.8217	-3,841	chief financial officer
Jan 01, 2024	riley antony a	acquired	-	-	9,375	chief financial officer

Which funds bought or sold FBRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	BML Capital Management, LLC	unchanged	-	-221,094	1,226,500	0.81%
Apr 23, 2024	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	unchanged	-	21.00	139	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-3,000	-	-%
Apr 05, 2024	CWM, LLC	sold off	-100	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.06	106,503	546,620	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	22.88	11,738	34,084	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	521,478	2,683,140	0.06%
Feb 20, 2024	Cable Car Capital LLC	new	-	1,669,680	1,669,680	1.73%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-7,125	-	-%
Feb 14, 2024	BVF INC/IL	unchanged	-	476,242	2,450,400	0.06%

Are Funds Buying or Selling FBRX?

Are funds buying FBRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FBRX

No. of Funds

Unveiling Forte Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	tybourne capital management (hk) ltd	9.99%	3,630,468	SC 13G
Feb 14, 2024	perceptive advisors llc	9.9%	3,633,635	SC 13G/A
Feb 14, 2024	farallon capital partners, l.p.	1.7%	633,514	SC 13G/A
Feb 14, 2024	alger associates inc	5.1%	1,838,965	SC 13G/A
Jan 11, 2024	bml investment partners, l.p.	4.8%	1,761,702	SC 13D/A
Jan 09, 2024	funicular funds, lp	5.59%	2,031,987	SC 13D/A
Jan 05, 2024	camac fund, lp	4.3%	1,577,176	SC 13D/A
Sep 15, 2023	bml investment partners, l.p.	4.78%	1,735,075	SC 13D/A
Sep 12, 2023	alger associates inc	5.1%	1,838,965	SC 13G
Sep 08, 2023	perceptive advisors llc	9.9%	3,627,775	SC 13G

Recent SEC filings of Forte Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	S-8	Employee Benefits Plan
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	10-K	Annual Report
Feb 16, 2024	8-K/A	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Forte Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Forte Biosciences, Inc. News

Latest updates

Forte Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4
Revenue	-70.1%	0.00	0.00	0.00	0.00	6.00	12.00	18.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Operating Expenses	-81.1%	2.00	11.00	1.00	1.00	17.00	19.00	17.00	15.00	13.00	-	-	-	-	-	-	-	-	-
S&GA Expenses	140.7%	1.00	-1.65	0.00	0.00	4.00	3.00	4.00	3.00	2.00	-	-	-	-	-	-	-	-	-
R&D Expenses	-58.6%	3.00	8.00	13.00	12.00	12.00	16.00	12.00	13.00	10.00	8.00	8.00	7.00	7.00	7.00	8.00	7.00	6.00	-
Interest Expenses	129.4%	1.00	0.00	2.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	-
Income Taxes	-	-	-	-	-	-	0.00	2.00	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-10.58	-18.73	-	-	-19.41	1.00	-	-	-	-9.95	-	-	-	-	-	-	-
Net Income	80.6%	-2.05	-10.58	-0.69	-0.63	-1.18	-19.60	-0.38	-16.09	-12.88	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-18.6%	39.00	48.00	31.00	37.00	42.00	45.00	40.00	41.00	43.00	47.00	53.00	57.00	61.00	23.00	28.00	19.00	8.00	71.00	85.00	95.00	103
Current Assets	-18.6%	38.00	47.00	31.00	36.00	42.00	45.00	39.00	40.00	43.00	47.00	52.00	56.00	60.00	22.00	28.00	15.00	8.00	60.00	73.00	82.00	98.00
Cash Equivalents	-19.6%	37.00	46.00	20.00	36.00	41.00	44.00	39.00	40.00	42.00	46.00	51.00	55.00	59.00	20.00	28.00	4.00	7.00	8.00	8.00	31.00	5.00
Net PPE	11.2%	0.00	0.00	0.00	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	1.00	0.00	4.00	4.00	4.00	4.00
Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.00	17.00	51.00	49.00	50.00	45.00
Current Liabilities	-50.9%	4.00	7.00	6.00	4.00	3.00	2.00	2.00	1.00	2.00	4.00	3.00	2.00	2.00	2.00	3.00	13.00	2.00	42.00	17.00	16.00	17.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.00	24.00	26.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.00	24.00	26.00
Shareholder's Equity	-12.6%	35.00	40.00	25.00	33.00	39.00	43.00	38.00	40.00	42.00	44.00	50.00	55.00	59.00	20.00	25.00	2.00	11.00	20.00	36.00	45.00	58.00
Retained Earnings	-5.3%	-118	-112	-102	-93.80	-87.04	-82.20	-78.80	-75.70	-73.17	-69.80	-62.10	-56.26	-51.46	-46.90	-41.80	-289	-4.97	-268	-250	-232	-215
Additional Paid-In Capital	0.5%	154	153	128	127	126	125	117	116	115	113	112	111	110	67.00	67.00	292	0.00	289	286	278	274
Accumulated Depreciation	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	-	-	-	3.00
Shares Outstanding	0.1%	36.00	36.00	21.00	21.00	21.00	21.00	15.00	15.00	15.00	14.00	14.00	13.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	20.00	-	-	-	18.00	-	-	-	396	-	-	-	72.00	-	-	-	223	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	0.8%	-8,969	-9,037	-5,496	-5,204	-2,893	-1,940	-1,377	-1,975	-3,582	-5,127	-3,938	-4,030	-3,803	-7,739	-4,016	-2,865	-653	-553	16,117	-17,682	-11,943
Share Based Compensation	1.0%	780	772	855	877	860	906	1,194	1,055	1,238	1,473	1,008	495	555	375	24.00	2.00	31.00	2.00	-1,997	2,000	1,750
Cashflow From Investing	-100.2%	-16.00	10,028	-	-	-	-	-	-	-	-	-	-	-	-1.00	-9,139	12,722	-89.00	-5,764	-406	6,097	756
Cashflow From Financing	-100.3%	-75.00	24,777	-24.00	6.00	-55.00	7,440	-110	-34.00	-39.00	-3.00	-29.00	27.00	42,393	166	24,063	45.00	-	-	3,086	1,770	28,518

FBRX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 21,862	$ 5,594
General and administrative	10,624	8,302
Total operating expenses	32,486	13,896
Loss from operations	(32,486)	(13,896)
Interest income	1,124	162
Other expense, net	(114)	(145)
Net loss	$ (31,476)	$ (13,879)
Net loss per share - basic	$ (1)	$ (0.8)
Net loss per share - diluted	$ (1)	$ (0.8)
Weighted average shares and pre-funded warrants outstanding, basic	31,571,039	17,383,531
Weighted average shares and pre-funded warrants outstanding, diluted	31,571,039	17,383,531
Comprehensive Loss:
Net loss	$ (31,476)	$ (13,879)
Unrealized gain on available-for-sale securities	4
Comprehensive loss	$ (31,472)	$ (13,879)

FBRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 37,125	$ 41,100
Prepaid expenses and other current assets	1,202	411
Total current assets	38,327	41,511
Property and equipment, net	109
Other assets	544	486
Total assets	38,980	41,997
Current liabilities:
Accounts payable	1,424	1,153
Accrued liabilities	2,242	2,026
Total current liabilities	3,666	3,179
Commitments and contingencies (Note 5)
Stockholders’ equity
Common stock, $0.001 par value: 200,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 36,335,105 and 21,000,069 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	36	21
Additional paid-in capital	153,794	125,841
Accumulated other comprehensive income	4
Accumulated deficit	(118,520)	(87,044)
Total stockholders’ equity	35,314	38,818
Total liabilities and stockholders' equity	$ 38,980	$ 41,997

About Forte Biosciences, Inc.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

CEO	Dr. Paul A. Wagner Ph.D.
WEBSITE	fortebiorx.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Forte Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Forte Biosciences, Inc.? What does FBRX stand for in stocks?

FBRX is the stock ticker symbol of Forte Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Forte Biosciences, Inc. (FBRX)?

As of Fri Apr 26 2024, market cap of Forte Biosciences, Inc. is 26.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FBRX stock?

You can check FBRX's fair value in chart for subscribers.

What is the fair value of FBRX stock?

You can check FBRX's fair value in chart for subscribers. The fair value of Forte Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Forte Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FBRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Forte Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether FBRX is over valued or under valued. Whether Forte Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Forte Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FBRX.

What is Forte Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, FBRX's PE ratio (Price to Earnings) is -0.83 and Price to Sales (PS) ratio is 647.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FBRX PE ratio will change depending on the future growth rate expectations of investors.